Antimicrobial peptides (AMPs) are naturally-occurring molecules that exhibit strong antibiotic properties against numerous infectious bacterial strains. Because of their unique mechanism of action, they have been touted as a potential source for novel antibiotic drugs. We present a summary of computational investigations in our lab aimed at understanding this unique mechanism of action, in particular the development of models that provide a quantitative connection between molecular-level biophysical phenomena and relevant biological effects. Our work is focused on protegrins, a potent class of AMPs that attack bacteria by associating with the bacterial membrane and forming transmembrane pores that facilitate the unrestricted transport of ions. Using fully atomistic molecular dynamics simulations, we have computed the thermodynamics of peptide-membrane association and insertion, as well as peptide aggregation. We also present a multi-scale analysis of the ion transport properties of protegrin pores, ranging from atomistic molecular dynamics simulations to mesoscale continuum models of single-pore electrodiffusion to models of transient ion transport from bacterial cells. Overall, this work provides a quantitative mechanistic description of the mechanism of action of protegrin antimicrobial peptides across multiple length and time scales.
References
[1]
Boucher, H.W.; Talbot, G.H.; Bradley, J.S.; Edwards, J.E.; Gilbert, D.; Rice, L.B.; Scheld, M.; Spellberg, B.; Bartlett, J. Bad bugs, no drugs: No ESKAPE! An update from the infectious diseases society of america. Clin. Infect. Dis 2009, 48, 1–12.
[2]
Zasloff, M. Antimicrobial peptides of multicellular organisms. Nature 2002, 415, 389–395.
[3]
Brogden, K.A. Antimicrobial peptides: Pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol 2005, 3, 238–250.
[4]
Kokryakov, N.V.; Harwig, S.S.L.; Panyutich, E.A.; Shevchenko, A.A.; Aleshina, G.M.; Shamova, O.V.; Korneva, H.A.; Lehrer, R.I. Protegrins: Leukocyte antimicrobial peptides that combine features of corticostatic defensins and tachyplesins. FEBS Lett 1993, 327, 231–236.
[5]
Mangoni, M.E.; Aumelas, A.; Charnet, P.; Roumestand, C.; Chiche, L.; Despaux, E.; Grassy, G.; Calas, B.; Chavanieu, A. Change in membrane permeability induced by protegrin 1: Implication of disulphide bridges for pore formation. FEBS Lett 1996, 383, 93–98.
Gidalevitz, D.; Ishitsuka, Y.; Muresan, A.S.; Konovalov, O.; Waring, A.J.; Lehrer, R.I.; Lee, K.Y. Interaction of antimicrobial peptide protegrin with biomembranes. Proc. Natl. Acad Sci. USA 2003, 100, 6302–6307.
[9]
Langham, A.A.; Ahmad, A.S.; Kaznessis, Y.N. On the nature of antimicrobial activity: A model for protegrin-1 pores. J. Am. Chem. Soc 2008, 130, 4338–4346.
[10]
Bolintineanu, D.S.; Hazrati, E.; Davis, H.T.; Lehrer, R.I.; Kaznessis, Y.N. Antimicrobial mechanism of pore-forming protegrin peptides: 100 pores to kill E. coli. Peptides 2010, 31, 1–8.
[11]
Bolintineanu, D.S.; Kaznessis, Y.N. Computational studies of protegrin antimicrobial peptides: A review. Peptides 2011, 32, 188–201.
[12]
Vivcharuk, V.; Kaznessis, Y. Free energy profile of the interaction between a monomer or a dimer of protegrin-1 in a specific binding orientation and a model lipid bilayer. J. Phys. Chem. B 2010, 114, 2790–2797.
[13]
Vivcharuk, V.; Kaznessis, Y.N. Dimerization of protegrin-1 in different environments. Int. J. Mol. Sci 2010, 11, 3177–3194.
[14]
Vivcharuk, V.; Kaznessis, Y. Thermodynamic Analysis of Protegrin-1 Insertion and Permeation through a Lipid Bilayer. 2011, 115, 14704–14712.
[15]
Kaznessis, Y.N. Statistical Thermodynamics and Stochastic Kinetics; Cambridge University Press: Cambridge, UK; p. 2012.
[16]
Talbot, J. Molecular thermodynamics of binary mixture adsorption: A scaled particle theory approach. J. Chem. Phys 1997, 106, 4696–4706.
[17]
Zuckermann, M.J.; Heimburg, T. Insertion and pore formation driven by adsorption of proteins onto lipid bilayer membrane-water interfaces. Biophys. J 2001, 81, 2458–2472.
[18]
Reiss, H.; Frisch, H.L.; Lebowitz, J.L. Statistical mechanics of rigid spheres. J. Chem. Phys 1959, 31, 369–380.
[19]
Matsuzaki, K.; Murase, O.; Fujii, N.; Miyajima, K. An antimicrobial peptide, magainin 2, induced rapid flip-flop of phospholipids coupled with pore formation and peptide translocation. Biochemistry 1996, 35, 11361–11368.
[20]
Huang, H.W.; Chen, F.Y.; Lee, M.T. Molecular mechanism of peptide-induced pores in membranes. Phys. Rev. Lett 2004, 92, 198304.
[21]
Mani, R.; Cady, S.D.; Tang, M.; Waring, A.J.; Lehrer, R.I.; Hong, M. Membrane-dependent oligomeric structure and pore formation of a beta-hairpin antimicrobial peptide in lipid bilayers from solid-state NMR. Proc. Natl. Acad Sci. USA 2006, 103, 16242–16247.
[22]
Bolintineanu, D.S.; Sayyed-Ahmad, A.; Davis, H.T.; Kaznessis, Y.N. Poisson-Nernst-Planck models of nonequilibrium ion electrodiffusion through a protegrin transmembrane pore. PLoS Comput. Biol 2009, 5, e1000277.
Sayyed-Ahmad, A.; Kaznessis, Y.N. Determining the orientation of protegrin-1 in DLPC bilayers using an implicit solvent-membrane model. PLoS One 2009, 4, e4799.
[25]
Langham, A.A.; Khandelia, H.; Schuster, B.; Waring, A.; Lehrer, R.; Kaznessis, Y. Correlation between simulated physicochemical properties and hemolycity of protegrin-like antimicrobial peptides: Predicting experimental toxicity. Peptides 2008, 29, 1085–1093.
[26]
Bolintineanu, D.S.; Langham, A.; Davis, T.H.; Kaznessis, Y. Molecular dynamics simulations of three protegrin-type anti-microbial peptides: interplay between charges at the termini, beta-sheet structure and amphiphilic interactions. Mol. Simul 2007, 33, 809–819.
[27]
Langham, A.A.; Waring, A.J.; Kaznessis, Y. Comparison of interactions between beta-hairpin decapeptides and SDS/DPC micelles from experimental and simulation data. BMC Biochem 2007, 8, 11.
[28]
Khandelia, H.; Kaznessis, Y. Structure of the antimicrobial beta-hairpin peptide protegrin-1 in a DLPC lipid bilayer investigated by molecular dynamics Simulation. Biochim. Biophys. Acta 2007, 1768, 509–520.
[29]
Khandelia, H.; Kaznessis, Y. Cation-π Interactions stabilize the structure of the antimicrobial peptide indolicidin near membranes: Molecular dynamics simulations. J. Phys. Chem. B 2007, 111, 242–250.
[30]
Langham, A.A.; Kaznessis, Y. Effects of mutations on the C-terminus of protegrin-1: A molecular dynamics simulation study. Mol. Simul 2006, 32, 193–201.
[31]
Khandelia, H.; Langham, A.; Kaznessis, Y. Driving engineering of novel antimicrobial peptides from simulations of peptide-micelle interactions. Biochim. Biophys. Acta 2006, 1758, 1224–1234.
[32]
Khandelia, H.; Kaznessis, Y. Molecular dynamics investigation of the influence of anionic and zwitterionic interfaces on antimicrobial peptides’ structure: Implications on peptide toxicity and activity. Peptides 2006, 27, 1192–1200.
[33]
Langham, A.A.; Khandelia, H.; Kaznessis, Y. How can protegrin-1 be both a potent antimicrobial and harmfully toxic? Molecular dynamics simulations of a beta-sheet antimicrobial peptide in micelles. Biopolym. Pept. Sci 2006, 84, 219–231.
[34]
Khandelia, H.; Kaznessis, Y. Molecular dynamics simulations of helical antimicrobial peptides in SDS micelles: What do point mutations achieve? Peptides 2005, 26, 2037–2049.
[35]
Sayyed-Ahmad, A.; Khandelia, H.; Kaznessis, Y.N. Relative free energy of binding between antimicrobial peptides and SDS or DPC micelles. Mol. Simul 2009, 35, 986–997.
[36]
Langham, A.; Kaznessis, Y. Molecular dynamics simulations of the N-terminus of HIV GP-41 fusion peptide in SDS micelles. J. Pept. Sci 2005, 14, 316–328.
[37]
Ostberg, N.; Khandelia, H.; Kaznessis, Y. Protegrin structure activity relationships: Using homology models of synthetic sequences to determine structural characteristics important for activity. Peptides 2005, 26, 297–306.
[38]
Mulakala, C.; Lambris, J.D.; Kaznessis, Y. A simple, yet highly accurate, QSAR model captures the complement inhibitory activity of compstatin. Bioorg. Med. Chem 2007, 15, 1638–1644.
[39]
Wang, W.; Mulakala, C.; Ward, S.C.; Jung, G.; Luong, H.; Pham, D.; Waring, A.J.; Kaznessis, Y.; Lu, W.; Bradley, K.A.; et al. Retrocyclins kill bacilli and germinating spores of Bacillus anthracis and inactivate anthrax lethal toxin. J. Biol. Chem 2006, 281, 32755–32764.
[40]
Chiu, T.-L.; Mulakala, C.; Lambris, J.D.; Kaznessis, Y.N. Development of a new pharmacophore model that discriminates active compstatin analogs. Chem. Biol. Drug Des 2008, 72, 249–256.
